Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4550 | leucovorin Wiki | 0.71 |
| drug4267 | Voraxaze Wiki | 0.71 |
| drug2359 | Methotrexate Wiki | 0.35 |
Navigate: Correlations HPO
There are 2 clinical trials
The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based structured prospective follow-up cohort of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. The study will include both treatment naïve patients starting their first DMT and patients switching from a previous first line DMT (escalation/second-line).
Description: - Proportion of patients with baseline EDSS ≤2.5 progressing to 12 months confirmed EDSS ≥3 among those over 3 years of follow up
Measure: Confirmed disease progression in patients with Expanded Disability Status Scale (EDSS) ≤2.5 at baseline Time: 3 yearsDescription: - Proportion of patients with baseline EDSS ≥2.5 experiencing 6 months confirmed EDSS increase of 1 point among those over 3 years of follow up
Measure: Confirmed disease progression in patients with EDSS ≥2.5 at baseline Time: 3 yearsDescription: - Change in MSIS-29 over 3 years of follow up (change from baseline; mean value ±SD)
Measure: Disease-related impact on daily life Time: 3 yearsDescription: - Rate of malignancy, cardiovascular disease, serious infections and all-cause mortality in populations on therapy and ever treated, respectively
Measure: Risk and side effect assessments Time: 3-9 yearsDescription: - The occurrence of serious adverse events (SAE) of all types that are possibly or likely related to DMT treatment
Measure: Occurence of Serious Adverse Reactions Time: 3-9 yearsDescription: - Comparison of mean number of relapses per year between the different treatments
Measure: Annual relapse rate Time: 3-9 yearsDescription: - Comparison of mean number of CEL on yearly MRI between the different treatments
Measure: Number of Contrast-enhancing lesions (CEL) Time: 3-9 yearsDescription: - Comparison of yearly increase in mean and median EDSS between the different treatments
Measure: Increase in EDSS Time: 3-9 yearsDescription: - Comparison of yearly proportion of patients with at least 1 step increase in EDSS between the different treatments
Measure: Proportion of patients with at least 1 step increase in EDSS Time: 3-9 yearsDescription: - Comparison of early proportion of patients with No Evidence of Disease Activity (NEDA) -2 (free of exacerbations, new/enlarged T2-lesions and occurrence of CEL) between the treatments
Measure: Proportion of patients with No Evidence of Disease Activity (NEDA) -2 Time: 3-9 yearsDescription: - Comparison of early proportion of patients with NEDA-3 (NEDA-2 plus no worsening of EDSS from baseline) between the treatments
Measure: Proportion of patients with NEDA-3 Time: 3-9 yearsDescription: - Comparison of mean levels of Neurofilament-Light chain (NFL) in serum between the different treatments
Measure: Levels of Neurofilament-Light chain (NFL) in serum Time: 3-9 yearsDescription: - Comparison of yearly brain atrophy rate measured as per cent brain parenchymal fraction (BPF) loss in relation to baseline values between the different treatments
Measure: Brain atrophy rate Time: 3-9 yearsDescription: - Comparison of time to drug discontinuation between the different treatments. Separate analyses will be performed depending on reason to drug discontinuation, mainly side effects and lack of efficacy
Measure: Time on drug Time: 3-9 yearsDescription: Comparison of patient satisfaction with their treatment using the Treatment Satisfaction Questionnaire (TSQ) between the treatments
Measure: Treatment satisfaction Time: 3-9 yearsDescription: - Comparison of health related QoL measured by EQ-5D between the treatments
Measure: Quality of life assessments Time: 3-9 yearsDescription: Comparison of fatigue measured by the Fatigue Scale for Motor and Cognitive Functions (FSMC) between the treatments
Measure: Fatigue Time: 3-9 yearsDescription: - Estimation of total societal costs per year after initiating treatment
Measure: Health economy Time: 3-9 yearsDescription: - Proportion of patients treated with RTX developing high-titer anti-RTX ADA
Measure: Occurrence of Anti-drug antibodies (ADA) Time: 3-9 yearsDescription: - Comparison of mean number of working hours per week between the treatments.
Measure: Employment rate Time: 3-9 yearsDescription: Number of hospital and ICU admittance in people with MS compared to population
Measure: Severity assessments of COVID-19 in MS Time: 1-2 years after COVID-19 epidemicDescription: Number of hospital and ICU admittance in people with MS in relation to DMD
Measure: Severity assessments of COVID-19 in MS in relation to DMD Time: 1-2 years after COVID-19 epidemicThe purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
Description: All serum samples will be tested via MTX immunoassay (measures MTX levels in addition to byproducts) as well as HPLC or mass spectroscopy which will reveal plasma concentrations of MTX and DAMPA separately.
Measure: number of patients that have significant reduction of serum methotrexate levels Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports